LONDON (Reuters) - An experimental cannabis drug has produced promising results in a small study of children with hard-to-treat epilepsy, sending shares in its British maker GW Pharmaceuticals to an all-time high.
The company, which grows cannabis under license at a secret location in Britain, is developing a range of so-called cannabinoid medicines. It already sells Sativex for spasticity caused by multiple sclerosis across Europe.
Also read: Charlie Gard’s Parents Abandon Fight to Take Ill Child to U.S
Read more